Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genakumab vs compound betamethasone for acute gouty arthritis
ChiCTR2600128798Phase 3Completed
- Sponsor
- Huashan Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of genakumab in gout and acute gout flare (2 arms), sponsored by Huashan Hospital. Primary endpoints: Change in VAS pain score (0-100 mm) in the target joint from baseline at 72 hours after treatment and Time to first new gout flare from baseline by Week 12. Started Jul 2026; status: completed.
02
Drugs
genakumab
03
Conditions
goutacute gout flare
Beyond the preview
Go deeper on ChiCTR2600128798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128798.